JP2010530238A5 - - Google Patents

Download PDF

Info

Publication number
JP2010530238A5
JP2010530238A5 JP2010512807A JP2010512807A JP2010530238A5 JP 2010530238 A5 JP2010530238 A5 JP 2010530238A5 JP 2010512807 A JP2010512807 A JP 2010512807A JP 2010512807 A JP2010512807 A JP 2010512807A JP 2010530238 A5 JP2010530238 A5 JP 2010530238A5
Authority
JP
Japan
Prior art keywords
seq
thrombin
amino acid
acid sequence
exosite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010512807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010530238A (ja
JP5699393B2 (ja
Filing date
Publication date
Priority claimed from GBGB0711779.9A external-priority patent/GB0711779D0/en
Application filed filed Critical
Publication of JP2010530238A publication Critical patent/JP2010530238A/ja
Publication of JP2010530238A5 publication Critical patent/JP2010530238A5/ja
Application granted granted Critical
Publication of JP5699393B2 publication Critical patent/JP5699393B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010512807A 2007-06-18 2008-06-18 トロンビンインヒビター Expired - Fee Related JP5699393B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0711779.9 2007-06-18
GBGB0711779.9A GB0711779D0 (en) 2007-06-18 2007-06-18 Thrombin inhibitor
PCT/IB2008/002109 WO2008155658A2 (en) 2007-06-18 2008-06-18 Thrombin inhibitor

Publications (3)

Publication Number Publication Date
JP2010530238A JP2010530238A (ja) 2010-09-09
JP2010530238A5 true JP2010530238A5 (enExample) 2011-08-04
JP5699393B2 JP5699393B2 (ja) 2015-04-08

Family

ID=38332312

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010512807A Expired - Fee Related JP5699393B2 (ja) 2007-06-18 2008-06-18 トロンビンインヒビター

Country Status (8)

Country Link
US (1) US9217027B2 (enExample)
EP (1) EP2185185B1 (enExample)
JP (1) JP5699393B2 (enExample)
CN (1) CN102026652B (enExample)
AU (1) AU2008264890A1 (enExample)
CA (1) CA2691243A1 (enExample)
GB (1) GB0711779D0 (enExample)
WO (1) WO2008155658A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102225966B (zh) 2004-10-19 2012-12-26 隆萨股份公司 用于固相肽合成的方法
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor
GB0907698D0 (en) * 2009-05-05 2009-06-10 Univ Singapore Method of modifying serine protease inhibitors
AU2011336345B2 (en) * 2010-12-02 2016-07-07 Becton, Dickinson And Company Blood collection devices containing blood stabilization agent
GB201121513D0 (en) 2011-12-14 2012-01-25 Cambridge Entpr Ltd Thrombin-binding antibody molecules and uses thereof
US9518128B2 (en) 2011-12-14 2016-12-13 Janssen Pharmaceuticals, Inc. Thrombin-binding antibody molecules
US20140220552A1 (en) * 2013-02-01 2014-08-07 Becton, Dickinson And Company Blood collection devices containing contact pathway inhibition additives
GB201310948D0 (en) * 2013-06-19 2013-07-31 Cambridge Entpr Ltd Screening methods
GB201406863D0 (en) * 2014-04-16 2014-05-28 Univ Leeds Compositions comprising variegin
EP3942931A1 (en) 2014-06-10 2022-01-26 Biomatrica, INC. Stabilization of thrombocytes at ambient temperatures
SG10201911414SA (en) * 2015-06-18 2020-02-27 Nat Univ Singapore Novel thrombin inhibitors
KR20250047404A (ko) 2015-12-08 2025-04-03 바이오매트리카 인코포레이티드 적혈구 침강 속도의 감소
NZ754781A (en) * 2016-12-16 2021-12-24 Univ Sydney Thrombin inhibitors for treatment of stroke and related coagulative disorders
BR102017005783A2 (pt) * 2017-03-21 2018-10-02 Fund Butantan processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
WO2019030706A1 (en) 2017-08-10 2019-02-14 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE IN ORTHOPEDIC SURGERY
WO2019035055A1 (en) 2017-08-16 2019-02-21 Janssen Pharmaceutica Nv ANTI-THROMBIN ANTIBODY MOLECULES AND METHODS OF USE WITH PLATELET ANTI-AGGREGATE AGENTS
ES3020087T3 (en) * 2020-09-21 2025-05-21 Instr Laboratory Co Detecting and monitoring oral anticoagulants or intravenous direct thrombin inhibitors in a blood sample

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341032C (en) 1987-01-23 2000-06-20 John L. Krstenansky Anticoagulant peptides
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
ATE198603T1 (de) 1993-10-25 2001-01-15 Ca Nat Research Council Bivalente thrombininhibitore
WO1996010638A1 (en) 1994-09-30 1996-04-11 Ppl Therapeutics (Scotland) Ltd. Alpha-1-antitrypsin and antithrombine-iii variants
GB9506212D0 (en) 1995-03-27 1995-05-17 Iaf Biochem Int Bifunctional thrombin inhibitors bearing highly truncated fibrinogen recognition exosite binding component
GB9613718D0 (en) 1996-06-29 1996-08-28 Thrombosis Res Inst Thrombin inhibitors
US5985833A (en) 1996-09-17 1999-11-16 Wisconsin Alumni Research Foundation Thrombin inhibitor
GB0209249D0 (en) * 2002-04-23 2002-06-05 Evolutec Ltd Anticoagulants
WO2004076484A1 (en) 2003-02-27 2004-09-10 National Research Council Of Canada Peptide inhibitors of thrombin as potent anticoagulants
GB0711779D0 (en) 2007-06-18 2007-07-25 Univ Singapore Thrombin inhibitor

Similar Documents

Publication Publication Date Title
JP2010530238A5 (enExample)
Gupta The lactate and the lactate dehydrogenase in inflammatory diseases and major risk factors in COVID-19 patients
RU2731507C1 (ru) Gla домены в качестве нацеливающих агентов
JP2007537197A5 (enExample)
JP2012512389A5 (enExample)
JP2019500346A (ja) 腎臓病の処置のための組成物と方法
US20230116704A1 (en) Antisense oligomers for treatment of conditions and diseases
JP6198277B2 (ja) 血液凝固促進に使用するための化合物
TW201103983A (en) Aptamer against chymase and use thereof
KR20240038967A (ko) Cug 반복을 표적화하기 위한 안티센스 화합물 및 방법
Devaux et al. An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection
EP3746151B1 (en) Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof
Gonzalez et al. Regulated intramembrane proteolysis of ACE2: A potential mechanism contributing to COVID-19 pathogenesis?
JP2024056926A (ja) 第Xa因子阻害剤に対する解毒剤
Bhowmick et al. Matrix metalloproteinase inhibition by heterotrimeric triple‐helical peptide transition state analogues
WO2013134249A1 (en) Adipose tissue targeted peptides
CN104450727A (zh) X-连锁低磷酸盐血症性佝偻病的致病基因及其编码蛋白质和应用
JP2004201692A5 (enExample)
US7309774B2 (en) Antiplasmin cleaving enzyme
EP3241904B1 (en) Factor xia-specific aptamers
JP2016520570A (ja) A型インフルエンザウイルス感染の治療又は予防に使用するためのpar−4アンタゴニスト
JP2011078414A (ja) ヒトカテプシンgのためのdnaに基づくアプタマー
JP2009539853A (ja) 抗プラスミン切断酵素の基質および阻害剤ならびにその使用
US20080057491A1 (en) Substrates and inhibitors of antiplasmin cleaving enzyme and methods of use
JP4727591B2 (ja) プロテアーゼ阻害活性を有する新規ポリペプチド